Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

Approval adds to Abbott’s line of products designed to optimize treatment of abnormally fast heart rhythms

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

September 22, 2017 — Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of the company's most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse ICD with the Tendril MRI pacing lead and Durata and Optisure high voltage leads adds another patient-centric benefit to the device and will help further improve access for patients suffering from abnormally fast heart rhythms who need an ICD and who may need an MRI scan in the future.

When electrical signals in the lower chamber of the heart fire erratically, the heart can beat abnormally fast – a condition known as ventricular tachycardia or tachyarrhythmia – which in turn leaves the heart unable to pump blood effectively. In addition to symptoms such as light-headedness, chest pains and shortness of breath, over time the condition can lead to a potentially life-threatening arrhythmia, heart failure, stroke or cardiac arrest. Abbott's ICD devices can monitor for and detect abnormally fast heart rhythms and deliver electricity to the heart to restore the heart's natural rhythm.

The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan if needed. In addition, patients previously implanted with an Ellipse device and Durata or Optisure leads can now undergo MRI scans.

The smaller shape and size of Ellipse ICD helps improve patient comfort once implanted, and Abbott engineered the device with features designed to optimize ICD therapy and improve patient safety. The features, known as Abbott's TailoredTherapy approach, include:

  • DeFT Response Technology: Allows physicians to adapt how therapy is delivered by the Ellipse ICD to ensure each patient receives therapy based on their unique need. The feature also helps ensure successful therapy delivery without the need to deliver an initial shock at the time of implant;
  • SecureSense: Abbott's SecureSense algorithm offers an additional level of protection for patients by providing proper sensing within the heart even in the presence of external interference (known as "lead noise") to safeguard against unnecessary therapy being delivered to the patient; and
  • DynamicTx: With Abbott's DynamicTx algorithm, physicians can be confident that their patient's devices are consistently evaluating the condition of the lead and adapting the path of the electrical impulse to deliver appropriate therapy.

 

As a further benefit, all therapy and other data captured by the Ellipse ICD can be directly, securely and wirelessly sent to a patient's physician through the Merlin.net Patient Care Network. This communication allows physicians to remotely monitor their patient's therapy and assess any need for intervention.

The latest labeling follows approval earlier this year of Abbott's Assurity MRI pacemaker and prior MR-conditional labeling approvals in Europe.

For more information: www.sjm.com

Related Content

Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Overlay Init